Amanda Witt, MD
Neuromuscular Medicine · Jackson, MSNPI 1386840619
Payments from drug & device makers
Across 290 payments — averaging $161.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$42K
- AstraZeneca$939
- CSL Behring$933
- UCB, Inc.$429
- AbbVie$218
- Argenx US, Inc.$159
- plus $2K from 35 others
What the payments were for
- Consulting fees$5,21011%
- Speaking & faculty fees$33,09371%
- Travel & lodging$3,0266%
- Food & beverage$5,25111%
- Education$1470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPINRAZA$40,521
How this compares
Too few neuromuscular medicine providers in Mississippito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 194 | $1,974,906 |
| Exondys-51Eteplirsen | 42 | $1,932,962 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 186 | $1,525,632 |
| VyvgartEfgartigimod Alfa-Fcab | 16 | $1,154,870 |
| Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc | 13 | $859,786 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 81 | $731,850 |
| Radicava OrsEdaravone | 50 | $701,091 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 24 | $424,895 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 40 | $337,100 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 21 | $254,990 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 53 | $208,758 |
| Pyridostigmine Bromide | 93 | $8,255 |
| Riluzole | 30 | $4,105 |
| Gabapentin | 150 | $3,421 |
| Mycophenolate Mofetil | 33 | $2,524 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Argenx US, Inc.Vyvgart, Vyvgart Hytrulo | $159 | $2,014,65629 claims |
| CSL BehringPrivigen | $933 | $1,974,906194 claims |
| Sarepta Therapeutics, Inc.Exondys-51 | $87 | $1,932,96242 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $85 | $731,85081 claims |
| PfizerPanzyga, Octagam | $15 | $463,74774 claims |
| Grifols USA, LLCGamunex-C | $86 | $337,10040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Mississippion file to place this against a meaningful peer group, so we don't.
Other neuromuscular medicine in Jackson
- Varun SreenivasanMadison$17K
- Richard OsnessKeesler Afb$148
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.